NL
Therapeutic Areas
EyePoint Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DURAVYU™ (EYP-1901) | Wet Age-related Macular Degeneration (AMD) | Phase 3 |
| EYP-2301 | Serious Retinal Diseases | Preclinical |
Leadership Team at EyePoint Pharmaceuticals
JS
Jay S. Duker
President, CEO and Board Director
GO
George O. Elston
Executive Vice President, Chief Financial Officer
RR
Ramiro Ribeiro
Chief Medical Officer
RH
Ron Honig
Chief Legal Officer & Company Secretary
MC
Michael Campbell
Chief Commercial Officer
IL
Isabelle Lefebvre
Chief Regulatory Officer
JL
Jennifer Leonard
Chief People Officer and SVP, IT
MJ
Michael J. Maciocio
Chief Manufacturing Officer
MS
Marcia Sellos-Moura
Chief Scientific Officer
GA
Göran Ando
Non-Executive Chairman of the Board